Innovative Auto-Injector Medical Device Company with FDA Approval Pathway

This listing presents an investment opportunity in an innovative medical device company focused on developing a technologically disruptive, patent-protected auto-injector. The company is on the verge of FDA approval for its emergency-use device, designed to deliver life-saving formulations, with an initial focus on displacing the EpiPen for anaphylactic shock treatment. The auto-injector serves as a versatile drug delivery platform, capable of handling a wide range of medications from thin liquids to thick biologics and vaccines. It features proprietary technology to protect glass cartridges and extend drug shelf-life, offering potential for out-licensing. The device is highlighted as technologically superior, durable, user-friendly, and cost-effective, being the world's smallest wearable auto-injector, making it ideal for military, first responders, and individuals with chronic conditions. The company anticipates economies of scale by using a common design for multiple drugs and expects to underprice competitors. The global auto-injector market is substantial and growing, with North America leading. The company boasts a strong team, including formulation experts and former industry executives, and has secured 13 Department of Defense contracts, granting sole sourcing rights for military sales valued at $6.9 million ($5 million active). The company is seeking $15 million in growth capital for FDA approval and manufacturing startup, with an epinephrine product launch projected for 2025 and significant revenue forecasts for 2027.